Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 1997

View Archived Issues

Sepracor's levalbuterol NDA accepted by FDA

ICOS and Abbott expand collaboration

Vertex and Alpha Therapeutic end hemoglobin collaboration

Anika completes phase III trial on Orthovisc

Activated Cell Therapy now named Dendreon Corporation

SmithKline Beecham and Incyte form diaDexus

Improved IOP-lowering prostaglandin analogues from Alcon

DuPont Merck discloses new anticoagulants

Large, long-term trial evaluates association between heart rate and mortality

Role of vitamin C in cardiovascular diseases investigated

Lipoprotein(a): new insights into the process of atherosclerosis

Subtype-selective NMDA receptor ligands reported

CV Therapeutics: Q2 1997 highlights

Celltech prepares PDE IV inhibitors

Vitronectin receptor antagonists described by Merck KGaA

Nippon Roche: products under development

DANAMI trial results presented

Texas Biotechnology: Q2 1997 highlights

Merck's asthma treatment receives first approvals

Genzyme General's Seprafilm receives approval in Japan

Neurobiological Technologies files IND for antiedema agent

AccuSite approved in Ireland and The Netherlands

Spotlight on adenosine A1 receptor agonists

DepoTech seeks Canadian approval for DepoCyt

Xoma: Q2 1997 highlights

NeuroSearch compound enters phase I for treatment of dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...